Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro™ (tirzepatide) injection Right
  4. How does tirzepatide compare with oral semaglutide?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How does tirzepatide compare with oral semaglutide?

Lilly is not currently conducting trials comparing tirzepatide with oral semaglutide.

US_cFAQ_TZP006_ORAL_SEMAGLUTIDE
US_cFAQ_TZP006_ORAL_SEMAGLUTIDE
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Oral Semaglutide

Eli Lilly and Company is not currently conducting phase 3 clinical trials assessing the efficacy and safety of tirzepatide compared with oral semaglutide as a treatment to improve glycemic control in people with type 2 diabetes (T2D).

Enclosed Prescribing Information

MOUNJARO™ (tirzepatide) injection, for subcutaneous use, Lilly

Date of Last Review: May 25, 2022

Additional related information:

  • Tirzepatide versus Semaglutide Once Weekly for People with Type 2 Diabetes (SURPASS-2)
  • How did Mounjaro™ (tirzepatide) compare with semaglutide 1 mg as add-on therapy to metformin in SURPASS-2?
Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly